Literature DB >> 33928277

A step-by-step model for a brief behavioural treatment for insomnia in Australian general practice.

Alexander Sweetman1, Nicholas A Zwar2, Nicole Grivell3, Nicole Lovato4, Leon Lack5.   

Abstract

BACKGROUND: Chronic insomnia is a prevalent and debilitating disorder managed in Australian general practice. The most effective and recommended first-line treatment for insomnia is cognitive behavioural therapy. This treatment has been translated to a condensed brief behavioural therapy for insomnia (BBTi), which is suitable for delivery in the general practice setting. There is evidence that BBTi improves insomnia, daytime functioning and quality of life, with effects persisting far beyond treatment cessation. BBTi appears to be a cost-effective treatment that is superior to sedative-hypnotic management.
OBJECTIVE: The aim of this article is to present a step-by-step approach for Australian general practitioners to administer BBTi. DISCUSSION: BBTi is an effective treatment for insomnia that may be administered in the Australian general practice setting. General practitioners may choose to use existing funding support to administer BBTi to treat chronic insomnia according to guideline recommendations.

Entities:  

Year:  2021        PMID: 33928277     DOI: 10.31128/AJGP-04-20-5391

Source DB:  PubMed          Journal:  Aust J Gen Pract


  2 in total

1.  Factors associated with self-reported health among New Zealand military veterans: a cross-sectional study.

Authors:  David McBride; Ariyapala Samaranayaka; Amy Richardson; Dianne Gardner; Daniel Shepherd; Emma Wyeth; Brandon de Graaf; Sarah Derrett
Journal:  BMJ Open       Date:  2022-05-25       Impact factor: 3.006

2.  Primary care management of chronic insomnia: a qualitative analysis of the attitudes and experiences of Australian general practitioners.

Authors:  Jenny Haycock; Nicole Grivell; Elizabeth Hoon; Anne Redman; Bandana Saini; Andrew Vakulin; Leon Lack; Nicole Lovato; Alexander Sweetman; Nicholas Zwar; Nigel Stocks; Oliver Frank; Sutapa Mukherjee; Robert Adams; R Doug McEvoy
Journal:  BMC Fam Pract       Date:  2021-07-22       Impact factor: 2.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.